Eldepryl
Developed to support motor function in Parkinson's disease, utilized to target dopamine degradation and alleviate symptoms of neurological impairment.
Strengths: 5 · 10mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Zelapar
- Therapeutic class
Monoamine Oxidase B Inhibitor
- Pharmacological class
MAO-B inhibitor
- Precautions and warnings
do not use with high-tyramine foods; monitor for orthostatic hypotension
- Minor side effects
dry mouth; nausea; headache
- Moderate side effects
insomnia; dizziness; orthostatic hypotension
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Orion Pharma
- Onset Time
2–4 weeks
- Duration
24 hours
- Storage instructions
Store below 25°C.
- Drug interactions
Caffeine; SSRIs; pethidine
- Age restrictions
Not for use in children.
- Pregnancy and breastfeeding
Use only if benefit outweighs risk.
Contraindications
concurrent use of serotonergic medicines; concurrent use of pethidine; hypersensitivity
Serious side effects
serotonin syndrome — requires immediate medical attention; hypertensive crisis — requires immediate medical attention; hallucinations — requires immediate medical attention
Patient summary
Developed to support motor function in Parkinson's disease, utilized to target dopamine degradation and alleviate symptoms of neurological impairment.
Mechanism of action
Selegiline is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B). By inhibiting this enzyme, it prevents the breakdown of dopamine in the brain, thereby increasing dopamine availability in the synaptic space.
Eldepryl
Developed to support motor function in Parkinson’s disease, utilized to target dopamine degradation and alleviate symptoms of neurological impairment.
Editorial Notes
- Active ingredient(s): Selegiline
- Listed indication(s): Parkinson’s Disease
Usually available as
- 180 tablets - 5 mg233-5-mg-2838
- 120 tablets - 10 mg233-10-mg-2844